Inhibiting HTLV-1 Protease: A Viable Antiviral Target-Reference-Cited by-同舟云学术

Inhibiting HTLV-1 Protease: A Viable Antiviral Target

Published:2021-02-23 Issue:3 Volume:16 Page:529-538
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Lockbaum Gordon J.¹^ORCID,Henes Mina¹,Talledge Nathaniel²^ORCID,Rusere Linah N.¹,Kosovrasti Klajdi¹,Nalivaika Ellen A.¹,Somasundaran Mohan¹,Ali Akbar¹^ORCID,Mansky Louis M.²,Kurt Yilmaz Nese¹^ORCID,Schiffer Celia A.¹^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States

2. Institute for Molecular Virology, Masonic Cancer Center, University of Minnesota − Twin Cities, Minneapolis, Minnesota 55455, United States

Funder

National Institute of Allergy and Infectious Diseases

National Institute on Drug Abuse

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.0c00975

Reference71 articles.

1. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

2. A New Subtype of Human T-Cell Leukemia Virus (HTLV-II) Associated with a T-Cell Variant of Hairy Cell Leukemia

3. Global epidemiology of HTLV-I infection and associated diseases

4. Epidemiology, Treatment, and Prevention of Human T-Cell Leukemia Virus Type 1-Associated Diseases

5. Retroviral Coinfections: HIV and HTLV: Taking Stock of More Than a Quarter Century of Research

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance;Viruses;2024-09-05

2. Cell Culture Evaluation Hints Widely Available HIV Drugs Are Primed for Success if Repurposed for HTLV-1 Prevention;Pharmaceuticals;2024-06-05

3. Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease;The Lancet Microbe;2024-04

4. Development of Potential Inhibitors for Human T-lymphotropic Virus Type I Integrase Enzyme: A Molecular Modeling Approach;Current Computer-Aided Drug Design;2024-02

5. Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy;Expert Review of Neurotherapeutics;2023-11-07